Health
New Ozempic Rival Is About to Make Your Weight Loss Drugs Cheaper
- New Lilly obesity drug will cost around 21% less than Novo’s
- Weight-loss drug leaders will battle for insurers, patients
This article is for subscribers only.
An effective and massively popular weight-loss drug has made Novo Nordisk A/S billions of dollars and turned it into the most valuable company in Europe. With the US Food and Drug Administration approval of another option from Eli Lilly & Co. on Wednesday, the Danish drugmaker now has some serious competition.
Novo has reaped mega-profits from its obesity drug Wegovy by selling it for a premium price of $1,349 a month in the US — significantly higher than its diabetes drug, Ozempic, even though the two contain the exact same active ingredient.